Kai Nicol-Schwarz’s Post

A great article with some insightful statistics on the funding market for early-stage startups between January and April 2024.    Key insights include: - Across Europe the early-stage funding deal count has fallen from 444 deals to 312 deals, however the value of funding has remained the same at £1.2bn. - The UK is leading early-stage funding in Europe, having secured £269m. France ranks second having secured £233m and Germany third having received £181m. - Industry wide, B2B SaaS received the most funding at £295m, with Climate Tech second at £285m, and Healthtech third securing £270m. Interesting to see how early-stage funding dynamics are shifting and great to see the UK leading from the front! #startup #funding #investment #growth    https://lnkd.in/excnJpHs

🩺 European healthtech has made a healthy recovery, with the sector raising $2 billion in funding in Q3 according to new data from Dealroom.co Oncology startups picked up nearly $600 million for groundbreaking novel research into areas such as immunotherapies and precision medicine More good news for European tech included: ➡️ Total European tech funding is at $40.9 billion, on track to equal 2023’s total investment ➡️ Fintech funding bounced back to reach $1.6 billion, up 45% compared to the same time last year ➡️ GenAI companies have raised 8% of total European VC funding this year ➡️ Over 2,000 rounds of $2 million or more have been raised by European startups Thanks to Stefano De Marzo for covering today’s news for EU-Startups. We’re looking forward to seeing what the rest of 2024 holds! https://lnkd.in/ey2Gxz49 #europeanvc #vcfunding #healthtech #data

Bessemer Venture Partners Venture Partner has just released its new "State of HealthTech 2024" report during the HLTH USA conference (that ended yesterday). On that note, I’m excited to be an ambassador once again for HLTH Europe 2025, taking place in June in Amsterdam. The Bessemer Venture Partner report is mostly (only?) focusing on the #US. I am therefore writing a few thoughts on the State of HealthTech 2024, focusing on #Europe. 1️⃣ 𝐄𝐮𝐫𝐨𝐩𝐞 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐮𝐧𝐝𝐞𝐫𝐟𝐮𝐧𝐝𝐞𝐝 𝐜𝐨𝐦𝐩𝐚𝐫𝐞𝐝 𝐭𝐨 𝐭𝐡𝐞 𝐔𝐒 According to Galen Growth | Insights You Can Trust, funding in the U.S. was 4.2x higher than in Europe between Oct 23 and Oct 24 ($18.2B for the US vs $4.4B for Europe). The UK ($1.1B), Germany ($1B), and France ($0.8B) accounted for 77% of European funding ($3.4 billion together). Given that the U.S. #healthcare sector is 2.5x larger than Europe's, one might expect #HealthTech funding to be 2.5x greater (rather than 4.2x). 2️⃣ 𝐓𝐡𝐞 𝐔𝐊 𝐨𝐧𝐜𝐞 𝐥𝐞𝐝 𝐄𝐮𝐫𝐨𝐩𝐞, 𝐛𝐮𝐭 𝐧𝐨𝐰 𝐅𝐫𝐚𝐧𝐜𝐞 𝐡𝐚𝐬 𝐭𝐚𝐤𝐞𝐧 𝐭𝐡𝐚𝐭 𝐫𝐨𝐥𝐞 UK had a leading portfolio of HealthTech scale-ups, but: ➡️ Babylon (AI virtual care) went bankrupt ➡️ Exscientia (AI drug discovery) was acquired by Recursion for a fraction of its expected value and recently published disappointing results for its AI developed drug. ➡️ BenevolentAI (AI drug discovery) went public with a current market cap of $100M (8x less than its $766M total funding). France is now leading with its 2 locomotives: Doctolib & Alan. 3️⃣ 𝐖𝐞 𝐧𝐞𝐞𝐝 𝐚 𝐦𝐨𝐫𝐞 𝐮𝐧𝐢𝐟𝐢𝐞𝐝 𝐇𝐞𝐚𝐥𝐭𝐡𝐓𝐞𝐜𝐡 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐄𝐮𝐫𝐨𝐩𝐞 𝐭𝐨 𝐡𝐞𝐥𝐩 𝐭𝐡𝐞 𝐬𝐜𝐚𝐥𝐢𝐧𝐠 European-based scale-ups are now mature enough to expand across Europe. Though this complexity could benefit my business ;), I believe we need better alignment of digital policies across Europe. The reimbursement landscape and requirements vary widely between countries, adding unnecessary complexity and costs for scale-ups. Public entities like La Poste Santé & Autonomie (the HealthTech arm of the French postal service), which has a strong HealthTech portfolio and serves as a trusted third party, could play a key role in building a unified European HealthTech market. 4️⃣ 𝐓𝐡𝐞 𝐦𝐨𝐦𝐞𝐧𝐭 𝐨𝐟 𝐭𝐫𝐮𝐭𝐡: 𝐭𝐡𝐞 𝐟𝐮𝐭𝐮𝐫𝐞 𝐈𝐏𝐎𝐬 𝐨𝐟 𝐅𝐫𝐞𝐧𝐜𝐡 𝐮𝐧𝐢𝐜𝐨𝐫𝐧𝐬 𝐃𝐨𝐜𝐭𝐨𝐥𝐢𝐛 (𝐨𝐫 𝐀𝐥𝐚𝐧) Doctolib is currently valued at over $5 billion and continues to expand its product portfolio. I'm really curious to see if 1) Doctolib will go public, and 2) how the IPO will unfold. Alan is also gaining significant traction, with its core focus on the private insurance market, while also developing new care delivery models. Will they go public in 2025? #vc #privateequity

In Q3 2024, UK health tech and life sciences startups secured nearly $1 billion in venture capital funding, bringing the year-to-date total to $2.3 billion. This surge positions the sector as the fastest-growing in UK VC investment, surpassing enterprise software and trailing only fintech. Notably, half of the UK's new unicorns in 2024 are from this sector, including EyeBio, IntraBio, and IIElevenLabs. The femtech segment also saw significant growth, with Flo raising $200 million, becoming Europe's first femtech unicorn. https://lnkd.in/eQmP8Uiu

Sifted's April’s early-stage funding wrapup — what did we find? 👉 Deal activity for Europe’s early-stage startups was down in April; VCs invested €1.4bn spread across 312 pre-seed, seed and Series A rounds last month 👉 The UK maintained its early-stage crown for funding in Europe (€314m), followed by France (€272m), then Germany (€211m) 👉 B2B SaaS, climate tech and healthtech took the top three spots, pulling in €345m, €333m and €315m respectively. 👉 It was a big month for healthtech, as drug discovery and biotech took the first two spots, pulling €138m and €135.2m respectively Plus, we share 12 early-stage rounds that caught our eye... #funding #venturecapital #VC

In Q3 2024, UK health tech and life sciences startups secured nearly $1 billion in venture capital funding, bringing the year-to-date total to $2.3 billion. This surge positions the sector as the fastest-growing in UK VC investment, surpassing enterprise software and trailing only fintech. Notably, half of the UK's new unicorns in 2024 are from this sector, including EyeBio, IntraBio, and IIElevenLabs. The femtech segment also saw significant growth, with Flo raising $200 million, becoming Europe's first femtech unicorn. https://lnkd.in/esmk7PXw

After two years of decline, European healthtech funding is making a strong comeback, with $10.4B raised so far in 2024 – surpassing 2023’s $9.7B. And there’s still more to come as smaller rounds continue to be reported. Here’s a spotlight on Europe’s most active early-stage healthtech investors this year (pre-seed to Series A): - Calm/Storm (Vienna): 33 deals, backing digital health gems like Béa Fertility and Meela. - Sofinnova Partners (Paris): 32 deals, focusing on life sciences with investments like Asceneuron and Freya Biosciences. - Elaia Partners (Paris): 29 deals, including Doccla and Pixacare. - Zürcher Kantonalbank (Zurich): 22 deals, supporting Swiss startups like Hemotune and Qumea. - Scottish Enterprise (Glasgow): 23 deals, funding life sciences startups like Nebu-Flow. Other key players include YZR Capital (Munich), SFC Capital (London), and Verve Ventures (Zurich), each driving innovative healthtech solutions across Europe. The sector’s biggest raises? EraCal Therapeutics (€235M) and ITM Radiopharma (€188M), showing the diversity of innovation—from biotech to medtech. #HealthTech #Investment #Startups #Innovation

Rock Health's latest report reveals a promising rebound for U.S. digital health startups, with $5.7B raised in H1 2024, potentially matching or exceeding pre-pandemic funding levels. The HLTH discussion highlighted the focus on practical AI applications like billing and coding, while noting that startups face competition from established players. As the market remains uncertain, strategic M&A is emerging as the most viable exit strategy. If you’re a small company or startup looking for guidance in the industry, feel free to reach out or connect to exchange ideas. https://lnkd.in/e_727ajd

#ICYMI Earlier this month, Holly Scanlan and Natalie Peat shared their essential points on how a PR strategy can support start-ups seeking to transform into scaling businesses 👇

🎉 Exciting News: Attention Digital Health Startups! We’re launching a new "Investor Call" service at R2GConnect and kicking things off with Heal Capital, one of Europe’s leading dedicated venture capital funds for integrated HealthTech. Heal Capital is on the lookout for: #European HealthTech Startups | Pre-Seed to Series A If you’re building the next dominant #healthtech platform with a digital or data-driven approach and ambitious goals, they want to hear from you! - #InvestmentSize: €1-5 million - Focus #Areas: All therapeutic areas / Disease agnostic - #Region: Europe Want to learn more and apply? Check it out here: https://lnkd.in/ddCVG68g Investors: Try R2GConnect.com and place your own Investor Call for free. Our platform enhances the efficiency of scouting, evaluating, and selecting the best #HealthTech companies that match your investment interests. For a demo session please reach out to Sorin STIRCU, Partnerships Manager https://bit.ly/3TGL2kF   #StartupFunding #VentureCapital #InvestorCall #HealthTechInvesting #EarlyStageInvesting #InvestmentOpportunities #InvestorNetworking #DealFlow